One of the greatest challenges in treating brain diseases like Alzheimer’s, Parkinson’s, and brain cancers is the blood-brain barrier. This natural defense system keeps harmful substances out—but it also blocks potentially life-saving medicines. A new study out of Tokyo University of Science (TUS) brings us one step closer to overcoming this challenge with a powerful tool: cholesterol-modified heteroduplex oligonucleotides (Chol-HDOs).

A New Generation of Gene-Targeting Drugs

Gene therapies that use antisense oligonucleotides (ASOs)—short DNA strands that silence harmful genes—have shown great promise. But there’s a problem: ASOs are quickly cleared from the body and rarely reach the brain. Enter Chol-HDOs, an enhanced version that stays in the bloodstream longer and can successfully cross into brain tissue.

In a study published in the Journal of Controlled Release, researchers demonstrated that Chol-HDOs:

  • Remained in the bloodstream 10x longer than traditional ASOs.
  • Delivered five times more drug to the brain’s cerebral cortex than standard methods.
  • Bound tightly to lipoproteins like HDL and LDL, helping them hitch a ride through the body and into the brain (Yoshioka et al., 2025).

Smarter Drug Delivery via Lipoprotein Binding

What makes Chol-HDOs so effective? It’s all about their cholesterol “tag.” This tag enables them to latch onto serum proteins, especially HDL and LDL, allowing them to circulate longer and sneak past biological barriers.

This strong binding to lipoproteins also reduces how quickly they’re filtered out by the liver and kidneys. In experiments, co-administering scavenger receptor inhibitors helped even more Chol-HDOs reach brain tissues, indicating a promising route for enhancing drug delivery efficiency.

Implications for Medicines Development

For GMDP Academy learners and professionals in medicines development, this research is a signal to the future. It illustrates:

  • The importance of molecular design in overcoming biological barriers.
  • How pharmacokinetics and protein binding influence therapeutic effectiveness.
  • The potential for gene-modulating therapies to address massive unmet needs in neurology.

More than 55 million people are currently living with dementia globally, and over 300,000 are diagnosed with brain cancer annually. Innovations like Chol-HDOs could offer real hope where little exists today (Tokyo University of Science, 2025).

Training Tomorrow’s Innovators

At GMDP Academy, we emphasize not just technical knowledge but translational thinking. We challenge our students to ask:
“How can this molecule shape outcomes across the development lifecycle—from discovery to delivery in the most vulnerable patient populations?”

This mindset, paired with cutting-edge science, equips our learners to lead the next era of ethical, effective, and equitable therapeutic innovation.

References

Tokyo University of Science. (2025, April 16). Towards gene-targeting drugs capable of targeting brain diseases. https://www.tus.ac.jp/en/mediarelations/archive/20250415_9037.html

Yoshioka, Y., Yamamoto, S., Goto, A., Kusamori, K., Iwasaki, S., Nakayama, M., … & Nishikawa, M. (2025). Pharmacokinetics and protein binding of cholesterol-conjugated heteroduplex oligonucleotide. Journal of Controlled Release, 380, 787–799. https://doi.org/10.1016/j.jconrel.2025.02.025

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred